drugset / Trial / NCT06895811
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, single-center, open-label clinical trial designed to evaluate the clinical safety and tolerability of different doses of Prostate-Specific Membrane Antigen (PSMA)-Universal Chimeric Antigen Receptor (UCAR) T-lymphocytes (PSMA-UCAR T) for the treatment of patients with refractory castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2025-03-27
- Primary completion
- 2026-07
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PSMA-UCAR T | Cell therapy | 1 cells/kg | — |
| Subject | PSMA-UCAR T | Cell therapy | 3 cells/kg | — |
| Subject | PSMA-UCAR T | Cell therapy | 5 cells/kg | — |